Increased Incidence of Functional (Psychogenic) Movement Disorders in Children and Adults Amid the COVID-19 Pandemic
A Cross-sectional Study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 19, 2020
- Accepted February 19, 2021
- First Published April 14, 2021.
Article Versions
- Previous version (April 14, 2021 - 14:12).
- You are viewing the most recent version of this article.
Author Disclosures
- Mariam Hull, MD,
- Mered Parnes, MD and
- Joseph Jankovic, MD
- Mariam Hull, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mered Parnes, MD and
(1) Teva Pharmaceuticals
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The institution of Dr. Parnes has received research support from (1) Alexion
The institution of Dr. Parnes has received research support from (1) NIH
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joseph Jankovic, MD
Dr. Jankovic has received research/training funding from AbbVie Inc; Acadia Pharmaceuticals; Allergan, Inc; Biotek; Cerevel Therapeutics; CHDI Foundation; Dystonia Coalition; Emalex Biosciences, Inc; F. Hoffmann-La Roche Ltd; Huntington Study Group; Medtronic Neuromodulation; Merz Pharmaceuticals; Michael J Fox Foundation for Parkinson Research; National Institutes of Health; Neuraly, Inc.; Neurocrine Biosciences; ParkinsonÂs Foundation; Parkinson Study Group; Prilenia Therapeutics; Revance Therapeutics, Inc; Teva Pharmaceutical Industries Ltd.
NONE
NONE
Acta Neurologica Scandinavica, Neurology Medlink, Neurotherapeutics, Expert Review of Neurotherapeutics, Journal of ParkinsonÂs Disease, Toxins
NONE
Cambridge; Elsevier; Medlink: Neurology; Lippincott Williams and Wilkins; Wiley-Blackwell
NONE
Aeon BioPharma; Nuvelution Pharma, Inc; Teva Pharmaceutical Industries Ltd.
NONE
NONE
NONE
Allergan, Inc; CHDI Foundation; Civitas/Acorda Therapeutics; Dystonia Coalition; Dystonia Medical Research Foundation; F. Hoffmann-La Roche Ltd; Huntington Study Group; Medtronic Neuromodulation; Merz Pharmaceuticals; Michael J Fox Foundation for Parkinson Research; National Institutes of Health; Neurocrine Biosciences; ParkinsonÂs Foundation; Nuvelution; Parkinson Study Group; Pfizer Inc; Prothena Biosciences Inc; Psyadon Pharmaceuticals, Inc; Revance Therapeutics, Inc; Teva Pharmaceutical Industries Ltd; US WorldMeds.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Expert witness for defendant
- Section of Pediatric Neurology and Developmental Neuroscience (MH, MP), Texas Children's Hospital and Baylor College of Medicine; and Department of Neurology (MH, MP, JJ), Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX.
- Correspondence
Dr. Hull mariam.hull{at}bcm.edu
Article usage
Cited By...
The Nerve!: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.